Le comité de surveillance et de suivi (DSMB) recommande de poursuivre l’étude HERACLES sans modifications.…
MaaT Pharmafévrier 5, 2019
Lyon, France, November 2, 2018 – MaaT Pharma announced today that the company will present…
MaaT Pharmanovembre 6, 2018
Results from in silico analysis using MaaT Pharma’s data analysis platform, GutPrint, demonstrate therapeutic rationale…
MaaT Pharmaseptembre 18, 2018
MaaT Pharma receives world-wide exclusive license to technology co-developed with hematology and gastroenterology departments of…
MaaT Pharmajuin 21, 2018
MaaT Pharma, a clinical-stage biopharmaceutical company, received authorization from competent authorities to launch its phase…
MaaT Pharmamars 5, 2018
The French Microbiome company completed its first clinical study proving that Autologous Fecal Microbiota Transfer…
MaaT Pharmanovembre 30, 2017
Fin du recrutement patients pour l ’essai clinique Odyssée de MaaT Pharma 30 mois…
MaaT Pharmajuillet 20, 2017
Lyon (France), June 15, 2017. A few days after signing a strategic partnership for the…
MaaT Pharmajuin 15, 2017
MaaT Pharma et Biocodex s’associent pour industrialiser le Transfert de Microbiote Fécal (TMF) et développer…
MaaT Pharmajuin 8, 2017
